The Role of Tumor Infiltrating Lymphocyte (TIL) Therapy in NSCLC

An expert in thoracic oncology, Adam J. Schoenfeld, MD, provides key insight into the use of cell therapy in non-small cell lung cancer after first-line treatment and highlights the potential for tumor-infiltrating lymphocyte (TIL) therapy depending on results from ongoing clinical trials.